Trabodenoson

Summary

Trabodenoson (CHEMBL3545407) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including ocular hypertension and open-angle glaucoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 5
• Chemistry: 380.36 Da · C15H20N6O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545407
Name	Trabodenoson
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	11610599
Molecular formula	C15H20N6O6
Molecular weight	380.36
InChIKey	AQLVRTWKJDTWQQ-SDBHATRESA-N

SMILES: C1CCC(C1)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO[N+](=O)[O-])O)O

IUPAC name: [(2R,3S,4R,5R)-5-[6-(cyclopentylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl nitrate

Also known as: INNO-8875, Ino-8875, PJ-875, Trabodenoson, TRABODENOSON

Patent coverage: 36 distinct patent families (142 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Adenosine A2 receptor, Adenosine receptor A1, Adenosine receptor A3.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADORA1	9.01	Ki	0.97	nM	CHEMBL_ACT_16290448
ADORA1	9.01	Ki	0.97	nM	CHEMBL_ACT_16493415
ADORA1	9.01	Ki	0.97	nM	CHEMBL_ACT_17602541
ADORA1	9.01	Ki	0.97	nM	CHEMBL_ACT_22396427
ADORA3	6.15	Ki	704	nM	CHEMBL_ACT_16300142
ADORA2A	5.33	Ki	4692	nM	CHEMBL_ACT_16350340

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ocular hypertension	3	MONDO:0006875	EFO:1001069
open-angle glaucoma	3	MONDO:0005338	EFO:0004190

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02565173	PHASE3	COMPLETED	Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma
NCT01123785	PHASE1/PHASE2	COMPLETED	A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
NCT01917383	PHASE2	COMPLETED	A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
NCT02829996	PHASE2	COMPLETED	Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG
NCT01123772	PHASE1	COMPLETED	Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).